Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue
Use
This test is useful for identifying MYC amplification to aid in the differentiation of cutaneous angiosarcomas from atypical vascular lesions after radiotherapy. Differentiation of post-radiation cutaneous angiosarcoma, a malignancy with a poor prognosis, from benign atypical vascular lesions is crucial as it influences treatment strategies. Angiosarcomas are characterized by MYC amplification, unlike benign lesions.
Special Instructions
A pathology report is required for testing to be performed. Additional tests, such as pathology consultation, may be ordered to complement this test. Suitable handling and preparation of the specimen are essential, including formalin-fixation of the tissue.
Limitations
This test is not FDA-approved and serves as an adjunct to clinical and pathologic data. Fixation methods other than formalin may not be successful, and decalcified tissues have about a 50% success rate. Failure to obtain FISH signals or insufficient tumor tissue may lead to test cancellation.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
LOINC Codes
- 101384-6
- 50397-9
- 69965-2
- 62356-1
- 42349-1
- 31208-2
- 80398-1
- 85069-3
- 18771-6
- 48767-8
- 62364-5
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tumor tissue block. Blocks fixed with other methods may be attempted but are less favorable. Fresh tissue specimens will be canceled unless embedded in paraffin.
Storage Instructions
Ambient (preferred); also acceptable refrigerated.
Causes for Rejection
Fresh tissue